Relievant Medsystems is a Minneapolis, MN-based commercial-stage medical device company focused on the diagnosis and treatment of vertebrogenic pain. Its core product is the Intracept Procedure, an FDA-cleared, commercially available treatment that uses targeted radiofrequency energy to stop the basivertebral nerve (BVN) from transmitting pain signals. The Intracept Procedure is typically performed in an outpatient surgery center, takes approximately one hour, and is intended to improve quality of life for indicated patients. Led by President and CEO Tyler Binney, the company commercializes and performs the Intracept Procedure. The company raised $50M in Series G funding. It plans to use the proceeds to expand operations and R&D efforts. Relievant Medsystems commercializes the Intracept Procedure, a minimally invasive treatment for vertebrogenic chronic low back pain supported by two Level I randomized controlled trials and long-term data beyond five years. The company completed a $70 million financing to accelerate U.S. commercialization and drive rapid commercial growth. Management said 2020 would be a record year for Relievant and expects greater adoption in 2021 following publication of five-year data showing sustained improvements in pain and function. Relievant estimates over five million U.S. CLBP patients are candidates for the Intracept Procedure and highlights the procedure’s potential to change the CLBP treatment paradigm. The company is privately held and is advancing physician adoption to make the treatment available to more patients and clinicians. Relievant Medsystems develops the Intracept Procedure, a transpedicular, minimally-invasive radiofrequency ablation targeting the basivertebral nerve to relieve chronic low back pain. The Intracept System is FDA-cleared for ablation of basivertebral nerves from L3 through S1 for patients with at least six months of pain and corresponding Modic changes. Treated patients report nearly immediate relief, and the outpatient procedure typically takes 60–90 minutes. The company plans to use new capital to commercialize the Intracept Procedure in the U.S. and to continue enrollment in its INTRACEPT Level I prospective randomized controlled trial at 20 U.S. sites. Relievant said the therapy targets more than five million indicated U.S. patients who have not responded to conservative care. The company was founded in 2006 and operates R&D and operations in Sunnyvale, CA while opening its corporate headquarters in Minneapolis, MN. Relievant Medsystems develops the INTRACEPT Intraosseous Nerve Ablation System to ablate basivertebral nerves within vertebral bodies for chronic low back pain (CLBP). The company received 510(k) clearance from the FDA for INTRACEPT in July 2016. Led by CEO Alex DiNello, Relievant is focused on commercializing INTRACEPT worldwide. The company plans to use recent financing to accelerate product, clinical and market development activities. The fundraising supports advancement of intraosseous basivertebral nerve ablation as a therapeutic option for CLBP. Relievant is positioned to move from regulatory clearance toward broader commercialization. Relievant Medsystems is a Redwood City, Calif.-based medical device company focused on basivertebral nerve ablation to treat chronic axial low back pain. It is developing the Intracept System, a minimally invasive procedure that uses radiofrequency energy delivered via percutaneous access into the vertebral body to ablate the basivertebral nerve. The company is led by CEO and President Alex DiNello. In March 2012 Relievant raised $30M in a Series D financing led by New Enterprise Associates with participation from Canaan Partners, Emergent Medical Partners, Morgenthaler Ventures and ONSET Ventures. NEA partner Justin Klein, M.D., joined the company’s board as part of the financing. Relievant intends to use the funds to advance and expand its worldwide clinical development programs.

Total raised

$264M

Funding rounds

6

Latest round

Series G

Latest activity

Apr 2023